Jeevan Scienti.

Why is Jeevan Scientific Technology Ltd falling/rising?

As of 31-Aug, Jeevan Scientific Technology Ltd's stock price is at 71.66, reflecting a decline of 2.04%. Despite a positive year-to-date performance, recent trends show the stock underperforming its sector and falling below key moving averages, indicating a downward trend.

As of 31-Aug, Jeevan Scientific Technology Ltd's stock price is falling, currently at 71.66, which reflects a decrease of 1.49 or 2.04%. The stock has underperformed its sector by 1.9% today and has been on a consecutive decline for the last two days, resulting in a total drop of 2.5% during this period. Over the past week, the stock has decreased by 3.48%, while the benchmark Sensex has only fallen by 0.53%. <BR><BR>Despite a positive year-to-date performance of 11.17% compared to the Sensex's decline of 9.70%, the stock's recent performance indicates a struggle, particularly as it is currently lower than the 5-day, 20-day, 50-day, and 100-day moving averages, although it remains above the 200-day moving average. Rising investor participation is noted, with a 17.5% increase in delivery volume on August 28 compared to the 5-day average, but this has not translated into positive price movement. Overall, the combination of recent declines, underperformance against the sector, and the stock's position relative to moving averages contribute to the current downward trend in Jeevan Scientific Technology Ltd's stock price.

Who are in the management team of Jeevan Scienti.?

The management team of Jeevan Scienti includes K Krishna Kishore (Vice Chairman & Managing Director), T Ravi Babu, G Bhanu Prakash, Koteswara Rao SSR (Chairman & Independent Director), K Rama Krishna Prasad, Snigdha Mothukuri (Executive Director & CEO), K. Jeevan Krishna, Sharvari Swapnil Shinde (Company Secretary), and Nageswar Rao Yarllagadda. They oversee the company's strategic direction and operations.

The management team of Jeevan Scienti includes the following individuals:<BR><BR>1. **K Krishna Kishore** - Vice Chairman & Managing Director<BR>2. **T Ravi Babu** - Director<BR>3. **G Bhanu Prakash** - Independent Director<BR>4. **Koteswara Rao SSR** - Chairman & Independent Director<BR>5. **K Rama Krishna Prasad** - Director<BR>6. **Snigdha Mothukuri** - Executive Director & CEO<BR>7. **K. Jeevan Krishna** - Director<BR>8. **Sharvari Swapnil Shinde** - Company Secretary<BR>9. **Nageswar Rao Yarllagadda** - Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

What does Jeevan Scienti. do?

Jeevan Scientific Technology Ltd is an independent clinical contract research organization providing technology-driven clinical research solutions. As of June 2026, it reported net sales of 18 Cr and a net profit of 1 Cr, with a market cap of INR 149 Cr.

Overview:<BR>Jeevan Scientific Technology Ltd is an Independent Clinical Contract Research Organization operating in the Healthcare Services industry within the Micro Cap market segment, providing reliable and technology-driven clinical research solutions.<BR><BR>History:<BR>Incorporated on 2nd February 1999 as Jeevan Softech Limited, the company later changed its name to Jeevan Scientific Technology Ltd. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 18 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 149 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 42.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.16 <BR>Return on Equity: -0.22% <BR>Price to Book: 2.08 <BR><BR>Contact Details:<BR>Address: Plot 1 & 2 Sai Krupa Enclave, Manikonda Jagir Nr Lanco Hills Hyderabad Telangana : 500008 <BR>Tel: 91-40-67364700 <BR>Email: info@jeevanscientific.com <BR>Website: http://www.jeevanscientific.com

Who are the peers of the Jeevan Scienti.?

Peers of Jeevan Scienti. include Take, Bilcare, Star Imaging, Choksi Laborator, Aspira Pathlab, and Aakaar Medical. Jeevan Scienti. has the highest 1-year return at 87.30%, while Star Imaging has the lowest at -38.32%.

Peers: The peers of Jeevan Scienti. are Take, Bilcare, Star Imaging, Choksi Laborator, Aspira Pathlab, Aakaar Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aakaar Medical and Star Imaging, while Below Average management risk is found at Take, Bilcare, Jeevan Scienti., Choksi Laborator, Aspira Pathlab. Good growth is noted at Bilcare, Choksi Laborator, Aakaar Medical, while Below Average growth is seen at Take, Jeevan Scienti., Aspira Pathlab, Star Imaging. Capital Structure is Excellent at Star Imaging, Average at Aspira Pathlab, and Below Average at Take, Bilcare, Jeevan Scienti., Choksi Laborator.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Jeevan Scienti. at 87.30%, while the peer with the lowest is Star Imaging at -38.32%. Jeevan Scienti.'s return significantly outperforms all peers. Additionally, Take and Star Imaging have negative six-month returns.

How big is Jeevan Scienti.?

As of 31st August, Jeevan Scientific Technology Ltd has a market capitalization of 149.00 Cr, with recent net sales of 71.02 Cr and a net profit of 3.48 Cr. Shareholder's funds are 49.94 Cr, and total assets amount to 77.37 Cr.

As of 31st August, Jeevan Scientific Technology Ltd has a market capitalization of 149.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Jeevan Scientific Technology Ltd reported Net Sales of 71.02 Cr and a Net Profit of 3.48 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 49.94 Cr and Total Assets of 77.37 Cr.

Which are the latest news on Jeevan Scienti.?

Should I buy, sell or hold Jeevan Scientific Technology Ltd?

When is the next results date for Jeevan Scientific Technology Ltd?

The next results date for Jeevan Scientific Technology Ltd is 13 August 2026.

The next results date for Jeevan Scientific Technology Ltd is scheduled for 13 August 2026.

Are Jeevan Scientific Technology Ltd latest results good or bad?

Jeevan Scientific Technology Ltd's latest results show strong revenue growth with a net profit increase of 13.38% and a 111.63% rise in net sales, but profitability remains a concern due to a significant drop in operating margins and negative return metrics, leading to investor skepticism reflected in a 1.30% stock decline. Overall, while revenue is improving, the company faces challenges in achieving sustainable profitability.

Jeevan Scientific Technology Ltd's latest results present a mixed picture. On one hand, the company reported a consolidated net profit of ₹1.61 crores for Q4 FY26, which is a 13.38% increase from the previous quarter, and net sales reached ₹21.29 crores, reflecting a remarkable 111.63% year-on-year growth. This marks the highest quarterly revenue in the company's recent history, suggesting improved client traction in its clinical research and data management services.<BR><BR>However, despite these positive revenue figures, the company continues to face significant challenges. The operating margin has compressed from 27.43% to 20.24% quarter-on-quarter, indicating rising cost pressures. Additionally, the company's profitability metrics remain concerning, with a negative return on equity (ROE) of -9.28% and a return on capital employed (ROCE) of -6.57% in the latest quarter. This suggests that while revenue is growing, the company is struggling to translate that growth into sustainable profitability.<BR><BR>The stock's decline of 1.30% to ₹83.26 following the results announcement reflects investor skepticism regarding the sustainability of this turnaround, especially given the company's history of operational volatility and loss-making status on a trailing twelve-month basis. Overall, while there are signs of improvement in revenue, the underlying profitability challenges raise questions about the company's long-term viability.

How has been the historical performance of Jeevan Scienti.?

Jeevan Scienti's historical performance shows fluctuating financial metrics, with net sales rising to 46.84 Cr in Mar'25 from 36.18 Cr in Mar'23, but still below the peak of 67.79 Cr in Mar'22. Operating profit improved to 8.06 Cr in Mar'25, while profit before and after tax returned to positive figures, indicating a recovery despite increased total assets and liabilities.

Answer:<BR>The historical performance of Jeevan Scienti shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Jeevan Scienti's net sales have seen a rise from 36.18 Cr in Mar'23 to 46.84 Cr in Mar'25, although they peaked at 67.79 Cr in Mar'22. The total operating income followed a similar pattern, increasing to 46.84 Cr in Mar'25 from 39.65 Cr in Mar'24, yet it remains below the 67.79 Cr recorded in Mar'22. The company's operating profit (PBDIT) has improved significantly, reaching 8.06 Cr in Mar'25 from 5.29 Cr in Mar'24, but it is still a decline from the 22.67 Cr in Mar'22. Profit before tax has shown a recovery to 0.05 Cr in Mar'25 from a loss of 1.60 Cr in Mar'24, while profit after tax also returned to a positive figure of 0.06 Cr in Mar'25, compared to a loss of 1.33 Cr in the previous year. The total assets of the company increased to 77.37 Cr in Mar'25 from 66.95 Cr in Mar'24, reflecting a growth trend, while total liabilities also rose to 77.37 Cr from 66.95 Cr, indicating a proportional increase in debt levels. Cash flow from operating activities improved to 10.00 Cr in Mar'25 from 2.00 Cr in Mar'24, showcasing a positive shift in cash generation capabilities.

Is Jeevan Scienti. overvalued or undervalued?

As of August 18, 2025, Jeevan Scienti. is considered overvalued and risky due to a negative PE ratio of -15.40, an EV to EBITDA ratio of 34.18, a low ROCE of 1.66%, and underperformance compared to peers and the Sensex.

As of 18 August 2025, the valuation grade for Jeevan Scienti. has moved from very attractive to risky, indicating a significant shift in its perceived value. The company appears to be overvalued based on its current metrics, particularly with a PE ratio of -15.40 and an EV to EBITDA ratio of 34.18, which are concerning indicators of financial health. Additionally, the ROCE stands at a mere 1.66%, further underscoring the company's struggles to generate returns.<BR><BR>When comparing Jeevan Scienti. to its peers, it stands out negatively. For instance, Sun Pharma. has a PE ratio of 34.14 and an EV to EBITDA of 23.11, while Cipla shows a PE of 23.52 and an EV to EBITDA of 16.57, both of which are significantly more favorable. The company's stock has also underperformed relative to the Sensex, with a year-to-date return of -20.48% compared to the Sensex's 4.01%. Overall, Jeevan Scienti. is assessed as overvalued given its poor financial ratios and relative performance against industry peers.

Who are the top shareholders of the Jeevan Scienti.?

The top shareholders of Jeevan Scienti are Krishna Kishore Kuchipudi with 12.22% and Durisala Desaiah with 5.24%. Individual investors hold a combined 42.99%, with no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Jeevan Scienti include Krishna Kishore Kuchipudi, who holds the highest promoter stake at 12.22%. The highest public shareholder is Durisala Desaiah, with a holding of 5.24%. Additionally, individual investors collectively hold 42.99% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Jeevan Scienti.?

As of June 2, 2025, Jeevan Scienti's technical trend has shifted to a moderate bearish stance, supported by bearish signals from MACD, Bollinger Bands, moving averages, and KST indicators across multiple time frames.

As of 2 June 2025, the technical trend for Jeevan Scienti has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating mixed signals. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the bearish outlook. Daily moving averages are also bearish, and both the weekly and monthly KST are bearish, further supporting the negative trend. The Dow Theory indicates a mildly bearish stance on both weekly and monthly charts. Overall, the combination of these indicators suggests a bearish sentiment in the market for Jeevan Scienti.

Has Jeevan Scienti. declared dividend?

Jeevan Scientific Technology Ltd has declared a 12% dividend, amounting to ₹1.2 per share, with an ex-date of September 21, 2022. Despite the dividend declaration, the company has experienced significant negative total returns over shorter periods, though it saw a positive return of 122.3% over the past five years.

Jeevan Scientific Technology Ltd has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: 21 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -23.55%, with a dividend return of 0%, resulting in a total return of -23.55%.<BR><BR>For the 1-year period, the price return was -17.17%, with a dividend return of 0%, leading to a total return of -17.17%.<BR><BR>Over the 2-year period, the price return was -7.49%, and the dividend return was 0%, resulting in a total return of -7.49%.<BR><BR>In the 3-year period, the price return was -36.89%, with a dividend return of 2.09%, culminating in a total return of -34.8%.<BR><BR>For the 4-year period, the price return was -55.82%, and the dividend return was 1.95%, leading to a total return of -53.87%.<BR><BR>Over the 5-year period, the price return was 113.4%, with a dividend return of 8.90%, resulting in a total return of 122.3%.<BR><BR>Overall, while Jeevan Scientific Technology Ltd has declared a dividend, the total returns over various periods show significant volatility, with negative returns dominating in shorter time frames, though there was a substantial positive return over the 5-year period.